VIVO News and Press, Meridian Bioscience Inc. From 01/13/21

CINCINNATI, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report first quarter fiscal 2021 financial results Friday, February 5, 2021. Jack Kenny, Chief Executive Officer, and...

Meridian could expand its testing supply windfall in 2021, as the world grapples with containing mutations of the COVID-19 virus. Balance sheet safety, profit margins, revenue growth, and current valuations are better than industry average. A large short interest position and a nu...

Gainers: [[VIVO]] +6%. [[ABUS]] +4.6%. [[AY]] +4.2%. [[EBON]] +3.5%. [[TSE]] +3.4%.Losers: [[ACLS]] -14%. [[DOGZ]] -8.5%. [[HX]] -7.8%. [[FIXX]] -5.9%. [[JRJC]] -2.1%. For further details see: AY, ABUS, ACLS and FIXX among after-hours movers

Meridian Bioscience ([[VIVO]] -2.0%) reported preliminary net revenue for Q1 of $92M compared to $47.4M a year ago, reflecting an increase of approximately 94% and better than consensus of $81.4M.Sees Life Science segment revenue of ~$62M, exceeding expectations due to the high demand fo...

CINCINNATI, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced preliminary financial results for the first quarter of fiscal 2021. Preliminary First Quarter Fiscal 2021 Res...

CINCINNATI, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced today its participation in the H. C. Wainright Bioconnect 2021 Virtual Conference. Jack Kenny, Chief Executive Officer,...

The seasonally-strongest baskets include gold and technology. The top stocks in each major sector right now. The best sectors include consumer goods, industrial goods, and financials. For further details see: The Top Stocks To Buy In The New Year

Meridian Bioscience ([[VIVO]] -3.3%) has been awarded funding of ~$1M by the National Institute of Health ((NIH)) Rapid Acceleration of Diagnostics initiative, to accelerate the launch of the company’s SARS-CoV-2 molecular diagnostic test on the Revogene platform.Recently,&#x...

CINCINNATI, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it has been awarded funding in the amount of approximately $1M by the National Institute of Health (NIH) Ra...

Meridian Bioscience ([[VIVO]] -1.0%) has submitted its application for Emergency Use Authorization ((EUA)) to the FDA for its SARS-CoV-2 molecular diagnostic test on the Revogene platform.The molecular diagnostic test is for the qualitative detection of the SARS-CoV-2 virus, with results...